CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates.

To assess the effects of Ile359 to Leu359 change on CYP2C9-mediated metabolism, we performed site-directed mutagenesis and cDNA expression in yeast for CYP2C9 and examined in detail the kinetics of seven metabolic reactions by wild-type CYP2C9 (Ile359) and its Leu359 variant. For the metabolism of all the substrates studied, the Leu359 variant exhibited smaller Vmax/Km values than did the wild-type. The differences in the Vmax/Km values between the wild-type and the Leu359 variant varied from 3.4-fold to 26.9-fold. The Leu359 variant had higher Km values than did the wild-type for all the reactions studied. Among the seven reactions studied, the greatest difference in the Vmax values between the wild-type and the Leu359 variant was for piroxicam 5'-hydroxylation (408 versus 19 pmol/min/nmol P450), whereas there were no differences in the Vmax values between the wild-type and the Leu359 variant for diclofenac 4'-hydroxylation and tolbutamide methylhydroxylation. These results indicate that the Ile359 to Leu359 change significantly decreases the catalytic activity of all the CYP2C9-mediated metabolisms studied, whereas the extent of the reduction in activity and changes of the kinetic parameters varies between substrates. Moreover, the amino acid substitution decreased the enantiomeric excess in the formation of 5-(4-hydroxyphenyl)-5-phenylhydantoin from phenytoin.

[1]  T. Leemann,et al.  Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. , 1993, Life sciences.

[2]  M. Hoshino,et al.  Simultaneous determination of citalopram and its metabolites by high-performance liquid chromatography with column switching and fluorescence detection by direct plasma injection. , 1995, Journal of chromatography. B, Biomedical applications.

[3]  I. Roots,et al.  Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. , 1987, The Journal of pharmacology and experimental therapeutics.

[4]  W. Trager,et al.  Genetic association between sensitivity to warfarin and expression of CYP2C9*3. , 1997, Pharmacogenetics.

[5]  H. Echizen,et al.  Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes , 1998, Clinical pharmacology and therapeutics.

[6]  W. Trager,et al.  Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. , 1996, Archives of biochemistry and biophysics.

[7]  T. Leemann,et al.  In vitro oxidation of oxicam NSAIDS by a human liver cytochrome P450. , 1992, Life sciences.

[8]  B. Hall,et al.  The primary structure of the alcohol dehydrogenase gene from the fission yeast Schizosaccharomyces pombe. , 1983, The Journal of biological chemistry.

[9]  J. Goldstein,et al.  Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. , 1997, Pharmacogenetics.

[10]  M C Meyer,et al.  Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. , 1999, Pharmacogenetics.

[11]  R. Kato,et al.  Nucleotide sequence of a human liver cytochrome P-450 related to the rat male specific form. , 1987, Journal of biochemistry.

[12]  J. Miners,et al.  Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. , 1991, Biochemical and biophysical research communications.

[13]  P. Srivastava,et al.  Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4'-hydroxylase cytochrome P-450 enzymes. , 1991, Molecular pharmacology.

[14]  K. Tanaka,et al.  High-frequency transformation method and library transducing vectors for cloning mammalian cDNAs by trans-complementation of Schizosaccharomyces pombe. , 1990, Nucleic acids research.

[15]  T. Aoyama,et al.  Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. , 1992, Chemical research in toxicology.

[16]  A. H. Phillips,et al.  Hepatic triphosphopyridine nucleotide-cytochrome c reductase: isolation, characterization, and kinetic studies. , 1962, The Journal of biological chemistry.

[17]  K. Furusho,et al.  Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy , 1997, Clinical pharmacology and therapeutics.

[18]  J. Miners,et al.  Allelic and functional variability of cytochrome P4502C9. , 1997, Pharmacogenetics.

[19]  J. Goldstein,et al.  Biochemistry and molecular biology of the human CYP2C subfamily. , 1994, Pharmacogenetics.

[20]  T. Ishizaki,et al.  Genetic analysis of CYP2C9 polymorphism in a Japanese population. , 1997, Pharmacogenetics.

[21]  T. Kamataki,et al.  Purification of human liver cytochrome P-450 catalyzing testosterone 6 beta-hydroxylation. , 1987, Journal of biochemistry.

[22]  F. Guengerich,et al.  Cloning and sequence determination of a complementary DNA related to human liver microsomal cytochrome P-450 S-mephenytoin 4-hydroxylase. , 1987, Biochemistry.

[23]  M. Relling,et al.  Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. , 1990, The Journal of pharmacology and experimental therapeutics.

[24]  M. Lai,et al.  Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. , 1995, Pharmacogenetics.

[25]  H. Okayama,et al.  High–Level Expression of Human Lipocortin I in the Fission Yeast Schizosaccharomyces pombe Using a Novel Expression Vector , 1994, Bio/Technology.

[26]  O. Gotoh,et al.  Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. , 1992, The Journal of biological chemistry.

[27]  M H Tarbit,et al.  Genetic analysis of the human cytochrome P450 CYP2C9 locus. , 1996, Pharmacogenetics.

[28]  G. Shenfield,et al.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.

[29]  D. Lewis,et al.  The CYP2 family: models, mutants and interactions. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[30]  D. Shen,et al.  Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[31]  L. Li,et al.  Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen. , 1998, Archives of biochemistry and biophysics.

[32]  J. Miners,et al.  Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. , 1993, The Biochemical journal.

[33]  J. Goldstein,et al.  Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. , 1993, Molecular pharmacology.